154 related articles for article (PubMed ID: 21764428)
1. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial.
Moore CM; Robertson NL; Jichi F; Damola A; Ambler G; Giganti F; Ridout AJ; Bott SR; Winkler M; Ahmed HU; Arya M; Mitra AV; McCartan N; Freeman A; Jameson C; Castro R; Gambarota G; Whitcher BJ; Allen C; Kirkham A; Emberton M
J Urol; 2017 Apr; 197(4):1006-1013. PubMed ID: 27871928
[TBL] [Abstract][Full Text] [Related]
3. WITHDRAWN: Cernilton for benign prostatic hyperplasia.
Wilt TJ; Macdonald R; Ishani A; Rutks I; Stark G
Cochrane Database Syst Rev; 2011 May; 2011(5):CD001042. PubMed ID: 21563128
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.
Thomson A
Core Evid; 2005; 1(2):143-56. PubMed ID: 22500150
[TBL] [Abstract][Full Text] [Related]
5. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.
Shore N; Tutrone R; Efros M; Bidair M; Wachs B; Kalota S; Freedman S; Bailen J; Levin R; Richardson S; Kaminetsky J; Snyder J; Shepard B; Goldberg K; Hay A; Gange S; Grunberger I
World J Urol; 2018 May; 36(5):801-809. PubMed ID: 29380128
[TBL] [Abstract][Full Text] [Related]
6. Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study.
Daniels JP; Mirocha J; Adjei M; Moreira D; Freedland SJ
J Urol; 2024 Jan; 211(1):101-110. PubMed ID: 37873943
[TBL] [Abstract][Full Text] [Related]
7. Randomized Placebo-Controlled Clinical Trial of Dutasteride for Reducing Heavy Drinking in Men.
Covault J; Tennen H; Feinn R
J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):223-231. PubMed ID: 38684046
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases.
Yang DY; Seo WW; Park RW; Rhee SY; Cha JM; Hah YS; Jeong CW; Kim KJ; Yang HJ; Kim DK; Ha JY
World J Mens Health; 2024 May; ():. PubMed ID: 38772542
[TBL] [Abstract][Full Text] [Related]
9. Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese.
Hung SC; Chang LW; Hsiao TH; Lin GC; Wang SS; Li JR; Chen IC
Hum Genomics; 2024 May; 18(1):49. PubMed ID: 38778357
[TBL] [Abstract][Full Text] [Related]
10. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Thompson IM
Prostate; 2009 Sep; 69(12):1303-11. PubMed ID: 19475640
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada.
Sayani A; Ismaila A; Walker A; Posnett J; Laroche B; Nickel JC; Su Z
Can Urol Assoc J; 2014; 8(1-2):E1-7. PubMed ID: 24454593
[TBL] [Abstract][Full Text] [Related]
12. Beta-sitosterols for benign prostatic hyperplasia.
Wilt T; Ishani A; MacDonald R; Stark G; Mulrow C; Lau J
Cochrane Database Syst Rev; 2000; 1999(2):CD001043. PubMed ID: 10796740
[TBL] [Abstract][Full Text] [Related]
13. The remote effects of intravitreal anti-VEGF therapy.
Balta F; Merticariu M; Taban C; Neculau G; Merticariu A; Muresanu D; Badescu D; Jinga V
J Med Life; 2016; 9(4):392-398. PubMed ID: 27928444
[No Abstract] [Full Text] [Related]
14. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.
Neuhouser ML; Schenk J; Song YJ; Tangen CM; Goodman PJ; Pollak M; Penson DF; Thompson IM; Kristal AR
Prostate; 2008 Sep; 68(13):1477-86. PubMed ID: 18618736
[TBL] [Abstract][Full Text] [Related]
15. Effect of dose reduction of dutasteride in combination with alpha-blockers in patients with lower urinary tract symptoms/benign prostatic enlargement.
Abou-Farha M; Hagras A; Nagla S
Urol Ann; 2024; 16(2):120-124. PubMed ID: 38818435
[TBL] [Abstract][Full Text] [Related]
16. Transurethral resection of prostate and bleeding: A prospective randomized, double blind, placebo controlled trial to see efficacy of short term use of Finasteride and Dutasteride on operative blood loss and prostatic micro-vessel density.
Bansal A; Arora A
J Endourol; 2017 Jan; ():. PubMed ID: 29641345
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Thorpe RJ; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Yates C
Prostate; 2024 Apr; 84(5):460-472. PubMed ID: 38192023
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the clinical effect of dutasteride therapy for benign prostatic hyperplasia when initiated at different time points: A multicentre, observational, retrospective chart review study.
Shima Y; Kawano Y; Kobayashi A; Yamanishi T; Takeda H; Palacios-Moreno JM; Yamada M; Masumori N
Int J Clin Pract; 2019 Sep; ():e13418. PubMed ID: 31508878
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Kratz M; Thompson IM
Am J Epidemiol; 2010 Mar; 171(5):571-82. PubMed ID: 20142396
[TBL] [Abstract][Full Text] [Related]
20. TESTOSTERONE AND SERUM ZINC LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA.
Radhi G; Hilal N; Abdul-Aziz M
Georgian Med News; 2023; (340-341):81-86. PubMed ID: 37805879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
